drugset / Trial / NCT02178358
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2157299 in participants with hepatocellular carcinoma.
Timeline
- Start
- 2014-08-08
- Primary completion
- 2017-06-30
- Completion
- 2021-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galunisertib | Small molecule | 150 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |